# SUPRAME (NCT06743126)

> SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06743126
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Immatics US, Inc.
- Conditions: Melanoma, Cutaneous Malignant
- Interventions: IMA203; nivolumab plus relatlimab; lifileucel; nivolumab; pembrolizumab; ipilimumab; Dacarbazine; temozolomide; paclitaxel; paclitaxel plus carboplatin; Albumin-Bound Paclitaxel
- Enrollment: 360
- Primary outcome: Progression-free survival assessed by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 3
- YouTube: 2
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=suprame-nct06743126

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06743126", "email": "<work email>"}; the inbox owner confirms by the emailed link.